Atea Pharmaceuticals, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging +5.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.56 | $-0.41 | +26.8% | Beat | |
| Q1 FY26 | $-0.60 | $-0.57 | +5.0% | Beat | |
| Q4 FY25 | $-0.49 | $-0.57 | -16.3% | Miss |
Back to AVIR overview · AVIR holders · AVIR KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.